ADDERALL 12.5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADDERALL 12.5 (ADDERALL 12.5).
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
| Metabolism | Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine. |
| Excretion | Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is pH-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%. |
| Half-life | The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect. |
| Protein binding | Approximately 15–20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence. |
| Bioavailability | Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release. |
| Onset of Action | Immediate-release formulation: Onset of CNS effects occurs within 30–60 minutes after oral administration. Extended-release (e.g., Adderall XR): Onset at 1–2 hours post-dose. |
| Duration of Action | Immediate-release: Duration of therapeutic effect is 4–6 hours. Extended-release: Duration is 8–12 hours. Clinical note: Duration may be shorter in children and longer in adults; tolerance may reduce apparent duration over time. |
| Molecular Weight | 135.21 |
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
| Dosage form | TABLET |
| Renal impairment | GFR 15-29 mL/min: reduce dose to 50% of usual; GFR <15 mL/min: use 50% of usual dose; hemodialysis: not removed, avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use. |
| Pediatric use | Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day. |
| Geriatric use | Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation. |
| 1st trimester | Risk of fetal cardiovascular malformations and oral clefts. Data from retrospective studies show increased risk with first-trimester exposure. Use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal growth restriction, preterm delivery, and neonatal withdrawal. Monitor fetal growth and neonatal adaptation. |
| 3rd trimester | Risk of neonatal withdrawal symptoms (hyperactivity, irritability, poor feeding) and growth restriction. Avoid use near term due to potential for neonatal tachycardia and feeding difficulties. |
Clinical note
Comprehensive clinical and safety monograph for ADDERALL 12.5 (ADDERALL 12.5).
| Placental transfer | Amphetamine crosses the placenta actively via monoamine transporters. Fetal levels reach 10-20% of maternal plasma concentrations. Documented in human studies. |
| Breastfeeding | Adderall (amphetamine) is excreted into breast milk in low concentrations. Peak milk concentrations occur 2-3 hours after dose. Relative infant dose is approximately 6-8% of maternal weight-adjusted dose. Monitor infant for agitation, poor sleep, and reduced weight gain. American Academy of Pediatrics recommends caution; consider alternative agents if possible. |
■ FDA Black Box Warning
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
Hypersensitivity to amphetamine or other sympathomimetic aminesConcurrent use or within 14 days of MAOIs (risk of hypertensive crisis)GlaucomaHyperthyroidismAgitated statesHistory of drug abuseSymptomatic cardiovascular diseaseModerate to severe hypertensionAdvanced arteriosclerosis
| Precautions | Risk of abuse and dependence, Serious cardiovascular events including sudden death, stroke, and myocardial infarction, Blood pressure and heart rate increases, Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression, Seizures in patients with seizure disorders, Visual disturbances, Growth suppression in children, Peripheral vasculopathy including Raynaud's phenomenon, Serotonin syndrome risk when used with serotonergic drugs |
| Food/Dietary | Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain; fetal growth via ultrasound (e.g., serial growth scans) and fetal heart rate monitoring. Assess for signs of preeclampsia and preterm labor. Monitor neonatal adaptation post-delivery. |
| Fertility Effects | Amphetamines may impair fertility in females by disrupting menstrual cycles and ovulation; in males, they may reduce sperm count and motility based on animal studies. Human data limited; advise deferring pregnancy until therapy cessation. |
| Clinical Pearls | ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules. |
| Patient Advice | Take exactly as prescribed; do not increase dose without consulting your doctor. · Swallow the capsule whole; do not chew, crush, or open it. · Avoid alcohol while taking this medication. · Do not drive or operate machinery until you know how this medication affects you. · Report any chest pain, shortness of breath, or fainting to your doctor immediately. · Store at room temperature away from moisture and heat. |